Prothena Corp Public (PRTA) FCF Margin (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly FCF Margin of 56.53% in Q1 2026, up 100.05% quarter-over-quarter from 111009.52% in Q4 2025, and up 194497.0% on a YoY basis from N/an in Q1 2025.
Prothena Corp Public (PRTA) FCF Margin (2013 - 2026) Analysis & Trends
Prothena Corp Public's FCF Margin history runs 14 years deep, the most recent figure standing at 56.53% for Q1 2026.
- In Q1 2026, FCF Margin rose 194497.0% year-over-year to 56.53%; the TTM figure through Mar 2026 stood at 140.55% (down 4587.0% YoY), while the FY2025 annual figure was 1690.6%, down 157936.0% from the prior year.
- FCF Margin was 56.53% for Q1 2026 at Prothena Corp Public, up from 111009.52% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 56.53% in Q1 2026 to a low of 146308.0% in Q1 2024.
- Historically, FCF Margin has averaged 17456.34% across 5 years, with a median of 2063.09% in 2022.
- The sharpest annual moves came in 2024 and 2025: FCF Margin slumped 14411777 bps in 2024, then soared 14441956 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 10.27% in 2022, then slumped by 161942 bps to 16641.46% in 2023, then jumped by 86 bps to 2252.24% in 2024, then slumped by 4829 bps to 111009.52% in 2025, then soared by 100 bps to 56.53% in 2026.
- The last three FCF Margin figures came in at 56.53% (Q1 2026), 111009.52% (Q4 2025), and 1680.12% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 56.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.53% |
| Dec 31, 2025 | -111,009.52% |
| Sep 30, 2025 | -1,680.12% |
| Jun 30, 2025 | -1,050.36% |
| Mar 31, 2025 | -1,888.44% |
| Dec 31, 2024 | -2,252.24% |
| Sep 30, 2024 | -4,659.28% |
| Jun 30, 2024 | 11.98% |
| Mar 31, 2024 | -146,308.00% |
| Dec 31, 2023 | -16,641.46% |
| Sep 30, 2023 | 10.69% |
| Jun 30, 2023 | -1,137.05% |
| Mar 31, 2023 | -2,190.23% |
| Dec 31, 2022 | -10.27% |
| Sep 30, 2022 | -2,063.09% |
| Jun 30, 2022 | -2,700.00% |
| Mar 31, 2022 | -3,246.92% |
| Dec 31, 2021 | -1,943.43% |
| Sep 30, 2021 | 80.40% |
| Jun 30, 2021 | 60.96% |